Agios Pharmaceuticals, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:AGIO) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 1.56 B1.47 B1.39 B1.3 B1.18 B Total liabilities 88.99 M101.68 M101.38 M104.11 M75.88 M Total equity 1.47 B1.37 B1.28 B1.19 B1.11 B Total liabilities & shareholders' equities 1.56 B1.47 B1.39 B1.3 B1.18 B Total debt ————— Net debt —————

News

AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up

Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?

Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone

AGIO Stock Surges 35% in Six Months: What's Driving It?

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event - Slideshow (NASDAQ:AGIO) 2026-06-15

Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript

Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue?

AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology Transcript

Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare Hematology - Slideshow (NASDAQ:AGIO) 2026-06-01

AGIO Halts Tebapivat Development in Myelodysplastic Syndromes

Agios: 'Sell' On Tebapivat Setback LR-MDS And Competitive PK Activator Drug Class (AGIO)